文献速递心血管乳腺MR

定量心脏磁共振组织特征能否充分识别化疗期间的心脏毒性?:时间和观察者变异性的影响

Can Quantitative CMR Tissue Characterization Adequately Identify Cardiotoxicity During Chemotherapy?: Impact of Temporal and Observer Variability.
PubMed 文献 · JACC Cardiovasc Imaging · 2019-12-18

研究纳入50名参与者(20例HER2阳性乳腺癌患者,其中10例有癌症治疗相关心功能障碍,10例无;30名健康对照),每3个月进行3次1.5-T心脏磁共振和生物标志物检测。结果显示有CTRCD患者原生T1、T2和ECV的时间变化大于无CTRCD患者,但生物标志物时间变化重叠,健康参与者的最小可检测差异接近CTRCD患者的平均时间变化,且个体患者参数变化与健康变异重叠。

要点

  • 有CTRCD患者原生T1时间变化27.2 ms(95%CI 20.8-39.3 ms),无CTRCD患者为12.4 ms(95%CI 9.5-17.9 ms)。
  • 健康参与者原生T1最小可检测差异为29 ms,接近CTRCD患者平均时间变化。
  • 心脏磁共振参数观察者间和观察者内变异性低(变异系数0.5%至4.3%)。

诊断标准与关键数值

  • 有CTRCD患者原生T1时间变化27.2 ms(95%CI 20.8-39.3 ms)vs 无CTRCD患者12.4 ms(95%CI 9.5-17.9 ms)。
  • 有CTRCD患者T2时间变化2.0 ms(95%CI 1.5-2.9 ms)vs 无CTRCD患者1.0 ms(95%CI 0.74-1.4 ms)。
  • 有CTRCD患者ECV时间变化2.1%(95%CI 1.5%-3.1%)vs 无CTRCD患者1.0%(95%CI 0.8%-1.5%)。
  • 健康参与者最小可检测差异:T1 29 ms、T2 3.0 ms、ECV 2.2%,接近CTRCD患者平均时间变化。
  • 心脏磁共振参数观察者间/观察者内变异系数0.5%至4.3%。

临床应用与阅片要点

  • 在个体患者中,原生T1、T2和ECV的时间变化与健康参与者时间变异性重叠,解读系列定量心脏磁共振结果时需考虑此变异。
  • 生物标志物时间变化在CTRCD患者与无CTRCD患者间存在重叠。
  • 这些方法的时间变异性可能对接受癌症治疗的个体患者的常规临床应用构成挑战。

局限性

  • 原文指出这些参数的准确性尚待进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The purpose of this study was to investigate the effect of the temporal and observer variability of cardiac magnetic resonance (CMR)-measured native T1, T2, and extracellular volume fraction (ECV) and serum biomarkers for the detection of cancer-therapeutics-related cardiac dysfunction (CTRCD).

BACKGROUND: Biomarkers and serial quantitative CMR tissue characterization may help identify early myocardial changes of CTRCD, but these parameters require both accuracy and reliability.

METHODS: A total of 50 participants (age 48.9 ± 12.1 years) underwent 3 CMR studies (1.5-T) and biomarker measurements (high-sensitivity troponin-I and B-type natriuretic peptide) at 3-month intervals: 20 with HER2-positive breast cancer (10 with and 10 without CTRCD), and 30 prospectively recruited healthy participants. T1 and T2 maps were obtained at 3 left ventricular short-axis locations. Temporal and observer variability were calculated as the coefficient of variation and as the standard error of the measurement (SEM) using repeated measures and 2-way analysis of variance. Minimal detected difference was defined as 2 × SEM.

RESULTS: Compared with the patients without CTRCD, those with CTRCD had larger temporal change in native T1 (27.2 ms [95% confidence interval (CI): 20.8 to 39.3 ms] vs. 12.4 ms [95% CI: 9.5 to 17.9 ms]), T2 (2.0 ms [95% CI: 1.5 to 2.9 ms] vs. 1.0 ms [95% CI: 0.74 to 1.4 ms]), and ECV (2.1% [95% CI: 1.5% to 3.1%] vs. 1.0% [95% CI: 0.8% to 1.5%]). However, the temporal changes in biomarkers overlapped. The minimal detected difference for T1 (29 ms), T2 (3.0 ms), and ECV (2.2%) in healthy participants approached the mean temporal changes in patients with CTRCD. For individual patients with CTRCD, there was overlap in the temporal changes of all 3 parameters, and the variability in healthy participants with the least overlap for native T1. The interobserver/intraobserver variabilities for the CMR parameters were low (coefficient of variation 0.5% to 4.3%).

CONCLUSIONS: The temporal changes in both biomarkers and tissue characterization measures in individual patients overlap with the temporal variability in healthy participants and approach the minimal detectable temporal differences. While the accuracy of the parameters awaits further study, the temporal variability of these methods may pose challenges to routine clinical application in individual patients receiving cancer therapy.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Altaha MA, Nolan M, Marwick TH, et al. Can Quantitative CMR Tissue Characterization Adequately Identify Cardiotoxicity During Chemotherapy?: Impact of Temporal and Observer Variability. JACC Cardiovasc Imaging. 2019. PMID: 31864977. doi:10.1016/j.jcmg.2019.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。